Serum biomarkers and non-invasive indices for discriminating MASLD among adults with dysglycaemia

Objectives

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. Although dysglycaemia is a major risk factor, additional cardiometabolic disturbances contribute to the development of MASLD. This study aimed to identify parameters that distinguish MASLD among dysglycaemic individuals using body composition, anthropometric, biochemical, and imaging-based assessments.

Methods